---
layout: minimal-medicine
title: Ipilimumab
---

# Ipilimumab
### Generic Name
Ipilimumab

### Usage

Ipilimumab is a type of immunotherapy drug, specifically a monoclonal antibody. Its primary use is in the treatment of unresectable or metastatic melanoma (skin cancer that has spread).  It's also used in combination with other therapies for several other cancers. These include:

* **Advanced renal cell carcinoma:** Used in combination with nivolumab (another immunotherapy drug) as a first-line treatment for intermediate or poor-risk patients.
* **Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer:** Used with nivolumab in patients whose disease has progressed after treatment with standard chemotherapy.
* **Hepatocellular carcinoma:**  Used with nivolumab in patients who have already received treatment with sorafenib (a targeted therapy).
* **Metastatic non-small cell lung cancer (NSCLC):**  Used with nivolumab in adults whose tumors express PD-L1 (a protein that helps cancer cells evade the immune system) and do not have certain genetic mutations (EGFR or ALK).  It may also be used with nivolumab and platinum-based chemotherapy in this setting.
* **Malignant pleural mesothelioma:** Used with nivolumab as a first-line treatment.
* **Adjuvant treatment of cutaneous melanoma:** For patients who have undergone complete resection (surgical removal) of cutaneous melanoma with regional lymph node involvement greater than 1 mm, Ipilimumab is used to reduce the risk of the cancer recurring.


Ipilimumab works by blocking a protein called CTLA-4, which helps to regulate the immune system's response to cancer cells. By blocking CTLA-4, Ipilimumab helps the immune system to better recognize and attack cancer cells.

### Dosage

Ipilimumab is administered intravenously (IV) and the dosage varies greatly depending on the cancer being treated and whether it is used as a single agent or in combination with other drugs.  Precise dosing instructions must come directly from a healthcare professional.  **The information below is for general knowledge only and should not be interpreted as a prescription.**

**Examples of Dosages (Always follow your doctor's specific instructions):**

* **Metastatic Melanoma (single agent):** 3 mg/kg every 3 weeks for up to 4 doses.
* **Metastatic Melanoma (with nivolumab):** 3 mg/kg every 3 weeks with nivolumab on the same day, for up to 4 doses.  Nivolumab may continue as a single agent after this.
* **Adjuvant Melanoma:**  The dosing regimen is more complex and typically involves a higher initial dose followed by lower maintenance doses over a prolonged period (up to 3 years), administered every 3 weeks and then every 12 weeks.
* **Other Cancers:** Dosage and frequency will vary significantly depending on the type of cancer and the combination therapy used.  Ipilimumab is often administered in combination with nivolumab for other indications.


Pediatric dosages exist for some indications but must be determined by a physician specializing in oncology and pediatric care.  The safety and efficacy of Ipilimumab have not been fully established for all cancers in children under 12 years old.

### Side Effects

Ipilimumab can cause various side effects, ranging from mild to severe.  It's crucial to report any concerning symptoms to your healthcare provider immediately.

**Common Side Effects (occurring in >10% of patients):**

* Fatigue
* Diarrhea
* Rash
* Itchiness
* Cough
* Nausea
* Vomiting
* Loss of appetite
* Headache
* Abdominal pain
* Fever
* Anemia


**Serious but Less Common Side Effects (occurring in <10% of patients):**

* Severe allergic reactions
* Colitis (inflammation of the colon)
* Hepatitis (inflammation of the liver)
* Nephritis (inflammation of the kidneys)
* Pneumonitis (inflammation of the lungs)
* Endocrinopathies (hormonal disorders, such as thyroid problems or adrenal insufficiency)
* Heart problems (myocarditis)
* Neurological problems (neuritis, encephalitis)
* Severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis)


This is not an exhaustive list, and the frequency and severity of side effects vary greatly among individuals.

### How it Works

Ipilimumab works by blocking the cytotoxic T-lymphocyte antigen 4 (CTLA-4) protein.  CTLA-4 is a protein on the surface of T cells (a type of immune cell) that normally helps to suppress the immune response. By blocking CTLA-4, Ipilimumab allows T cells to become more active and better able to recognize and attack cancer cells.  This leads to an increased anti-tumor immune response.


### Precautions

* **Allergies:**  Ipilimumab should not be used by individuals with a known allergy to Ipilimumab or any of its components.
* **Autoimmune Diseases:** Ipilimumab should be used with extreme caution in individuals with active autoimmune diseases or a history of autoimmune disorders, as it can worsen these conditions.
* **Pregnancy and Breastfeeding:** Ipilimumab can harm a developing fetus.  Pregnant women should not use this medication.  Effective contraception is necessary during treatment and for three months afterward.  Breastfeeding is also discouraged during treatment and for three months after the final dose.
* **Other Medications:** Ipilimumab may interact with other medications, particularly those that affect the immune system or liver function.  It is essential to inform your doctor of all medications you are taking.
* **Infusion Reactions:**  Infusion reactions can occur.  Slow infusions can mitigate this risk, however, immediate medical attention should be sought if severe reactions occur.
* **Monitoring:**  Regular monitoring of blood counts, liver and kidney function, and hormone levels is essential during Ipilimumab treatment to detect and manage potential side effects.


### FAQs

* **Q: How long does it take for Ipilimumab to work?** A: The response to Ipilimumab can vary significantly among individuals.  Some patients may see a response within a few months, while others may not see a response at all. Regular monitoring is necessary to assess treatment effectiveness.

* **Q: How is Ipilimumab stored?** A:  Ipilimumab should be stored under specific temperature conditions as directed by your healthcare professional or pharmacist. Generally, it's refrigerated.

* **Q: What should I do if I miss a dose?** A: Contact your doctor immediately if you miss a dose of Ipilimumab. Do not try to adjust the dose yourself.


* **Q: Are there long-term side effects?** A: Yes, there is a potential for long-term side effects, particularly autoimmune-related issues.  Ongoing monitoring after the completion of treatment is important.

* **Q: Can I drink alcohol while taking Ipilimumab?** A:  It's best to avoid alcohol or limit consumption while on Ipilimumab, especially given the potential for liver side effects. Discuss alcohol use with your doctor.

**Disclaimer:** This information is for general knowledge and does not constitute medical advice.  Always consult with your healthcare provider for diagnosis, treatment, and any questions about Ipilimumab or other medications.  The provided dosage information is for illustrative purposes only and should not be used to self-medicate.  Always follow your physician's instructions.
